Objective To compare the accuracy of same-day therapyassessment PET/computed tomography (PET/CT) and conventional contrast-enhanced computed tomography (CECT) in patients with oropharyngeal squamous cell carcinoma (OPSCC).
F-FDG-PET/CT versus contrast-enhanced CT in patients with oropharyngeal squamous cell carcinoma: comparative effectiveness study Objective To compare the accuracy of same-day therapyassessment PET/computed tomography (PET/CT) and conventional contrast-enhanced computed tomography (CECT) in patients with oropharyngeal squamous cell carcinoma (OPSCC).
Methods A total of 110 (95 men and 15 women; mean age 59 years) patients with biopsy-proven OPSCC were evaluated with same-day PET/CT and CECT pair scans as part of follow-up therapy assessment. Scans were performed within 6 months after the completion of primary treatment (median time: 3.1 months; range: 0.5-6 months). PET/CT and CECT scans were reviewed retrospectively for residual primary site disease, and right and left cervical lymph node involvement. Histopathology or 6 month clinical/imaging follow-up were used as the gold standard. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated for the primary site and cervical nodal disease.
Results Of 110 OPSCC patients, 90.9% were human papilloma virus positive, 80.8% were stage 4, and 76.4% received chemoradiation as the primary treatment. The sensitivity, specificity, PPV, NPV, and accuracy of PET/CT and CECT were similar in the evaluation of the primary cancer site (PET/CT: 75.0, 91.5, 25.0, 99.0, and 90.9, respectively, versus CECT: 75.0, 90.6, 23.1, 99.0, and 90.0, respectively). In evaluating cervical lymph node involvement, PET/CT appeared to have higher accuracy (96.8 vs. 81.7%), specificity (97.7 vs. 81.7%), and PPV (45.8 vs. 16 .5%), comparable NPV (99.4% for both), and lower sensitivity (65 vs. 75%) compared with same-day CECT.
Conclusion Same-day PET/CT and CECT scans had comparable accuracy in the evaluation of primary tumor sites after completion of therapy in patients with OPSCC. PET/CT showed higher accuracy in the evaluation of cervical lymph node involvement. Nucl Med Commun 38:250-258 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Oropharyngeal squamous cell carcinoma (OPSCC) is the most common subtype of head and neck cancers, with an incidence of 12 000 new cases annually in the USA [1, 2] . Although the incidence of other head and neck cancers decreased in the last decade, the number of patients with OPSCC has increased because of oral human papilloma virus (HPV) infections. Palatine tonsil and base of the tongue are the most common sites of HPV-related head and neck carcinomas [3] . The other well-known risk factors associated with OPSCC are smoking and alcohol consumption [4] .
Standard of care therapy for OPSCC includes surgery, radiation therapy, or chemotherapy, either alone or in combination [5] . The National Comprehensive Cancer Network (NCCN) guideline recommends performing baseline post-treatment imaging in patients with T3-4 or N2-3 OPSCC to assess the primary site and neck within 6 months of treatment [6] . Some of the post-treatment changes include inflammation, fibrosis, and deformed anatomy because of surgery, decreasing the accuracy of response assessment, which may lead to delayed or unnecessary treatment [7] . Multiple imaging modalities such as PET/computer tomography (PET/CT), contrastenhanced computed tomography (CECT), and MRI are used for therapy assessment in these patients [7, 8] . The trend of performing post-treatment PET/CT in patients with OPSCC has increased over the last 10 years, whereas that of CT scan has decreased [9] .
Previous studies have reported post-treatment evaluation by PET/CT to be more accurate than by other conventional imaging modalities [10] [11] [12] . However, there is little knowledge comparing the value of same-day PET/CT and CECT in therapy assessment of patients with OPSCC. Two previous studies compared the posttreatment PET/CT and CT in head and neck cancers in different settings such as different time-points or lowdose noncontrast CT [13, 14] . The aim of the present study is to compare the accuracy of same-day PET/CT and CECT in therapy assessment of patients with OPSCC.
Methods

Patient selection and inclusion criteria
This is an Institutional Review Board approved study under a waiver of informed consent following the HIPPA guidelines. Using the PET/CT database, all patients with biopsy-proven OPSCC who had a PET/CT scan in our center from 2000 to 2013 were identified. Those patients who had a same-day PET/CT scan and head and neck CECT scan within 6 months from the completion of their primary treatment were included in the study. The 6-month time limitation was used following the NCCN guideline recommendation of performing an imaging therapy assessment within 6 months after the completion of treatment. A total of 110 patients, who fulfilled the criteria, were included in the study. Demographics and clinical information of these patients were extracted and are summarized in Table 1 . Patients' electronic medical records were reviewed till 6 months from the date of the scans and histopathological results or post imaging clinical information were recorded as the reference standard.
PET/CT protocol PET/CT scans for the assessment of patients with head and neck cancers were performed according to the institutional protocol. All patients were instructed to fast for at least 4 h before scanning, and their weight, height, and glucose level were recorded at the time of the PET study. The blood glucose level was less than 200 mg/dl for all patients and the fluorine-18 fluorodeoxyglucose ( 18 F-FDG) injected dose was 5.55 MBq/kg into one of the peripheral veins. After a 60 min uptake, patients were scanned by a whole-body PET from the clavicle to the mid-thigh, with the arms above the head, followed by a dedicated head and neck PET from the top of the head to the carina, with the arms by the side; a low-dose, noncontrast CT scan was performed after each PET scan for attenuation correction and anatomical coregistration purposes. The images were obtained using either a Discovery LS (two-dimensional) or a Discovery VCT (three-dimensional) (GE Healthcare, Waukesha, Wisconsin, USA 
CECT protocol
In our center, the requesting physicians order a same-day CECT scan in about half of the patients with head and neck cancers in the post-treatment setting. Immediately after the whole-body and head and neck PET/CT scans were acquired, a contrast-enhanced neck CT was performed using 100 ml contrast agent [Omnipaque-350 (iohexol) or Visipaque-320 (iodixinol)]. The neck CECT scan was acquired using the same scanner as PET/CT and the image parameters were as follows: helical, 120 kV, Smart mA, thickness 0.625, 8.0 noise index, and a 512 × 512 matrix with a beam collimation of 10 mm and a pitch of 0.984. The PET/CT and the head and neck CECT scans were acquired about 5 min apart. Image analysis and statistical analysis
The post-treatment PET/CT and neck CECT scans of all patients were read prospectively by a board-certified nuclear medicine physician and a senior radiology resident who was also board certified in nuclear medicine, respectively. The readers were completely blinded to any clinical patient information including the baseline and the follow-up images, with the exception of being aware that these were post-therapy assessment scans in patients with OPSCC. Almost all patients had a baseline PET/CT before therapy, but the readers were blinded to any previous imaging, other than the post-therapy PET/ CT and CECT performed on the same day. The PET/ CT images were read as positive or negative for residual disease at the primary tumor site (oropharynx), right and left side of the neck, and distant metastasis using the Hopkins Criteria [15, 16] . The CT scans were also read as positive or negative for residual disease at the primary site (oropharynx), right and left neck. Focal hyperenhancement with or without soft tissue mass or necrosis at the primary site was considered positive and for the neck lymph nodes, any of the following was considered positive: size more than 1.5 cm in level I or II, size more than 1 cm in other levels, abnormal enhancement, or presence of necrosis and abnormal morphology. Histopathological results and/or post imaging clinical information were recorded for the standard reference. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET/ CT and neck CECT scans for residual malignancy were assessed at the primary site and at the ipsilateral and contralateral neck sides. Using the SPSS 15.0 (SPSS Inc., Chicago, Illinois, USA) software, the χ 2 -test was performed to compare the results.
Results
Patient characteristics
A total of 110 (95 men and 15 women, mean age 59 9 years) patients were included in the study. Sixty percent (66/110) of the patients had the primary tumor at the base of the tongue and in 40% of the patients (44/110), it was located at the tonsil. Most of the patients (100/110, 90.9%) had an HPV-related OPSCC and stage 4 disease was the most common (89/110, 80.8%) stage at the initial presentation. The most common treatment modality was chemoradiotherapy (84/110, 76.4%). Table 1 summarizes the characteristics of the patients included in the study. A total of 110 PET/CT and 110 neck CECT scans were performed within 6 months from the completion of treatment and included in the analysis. The therapy assessment scans were performed with a median time of 3.1 months (range: 2-25.9 weeks; mean 13.1 weeks) after the completion of treatment.
Accuracy of follow-up PET/CT
Sensitivity, specificity, PPV, NPV, and accuracy for both PET/CT and neck CECT scans were measured in three different sites: primary cancer site, ipsilateral neck, and contralateral neck. The overall value of PET/CT and CECT scans was also calculated. A total of 11 residual disease sites were confirmed by histopathology (n = 8) and 6-month clinical follow-up (n = 3): four lesions in the primary site, five lesions in the ipsilateral neck, and two lesions in the contralateral neck.
Primary site
In detecting residual disease at the primary site, the PET/ CT scan showed 97 true negative (TN), one false negative (FN), three true positive (TP), and nine false-positive (FP) results, whereas CECT scans yielded 96 TN scans, one FN scan, three TP scans, and 10 FP scans for detecting residual disease at the primary site of cancer. Therefore, the sensitivity, specificity, PPV, NPV, and accuracy of PET/CT for detecting residual disease in the oropharynx were 75, 91.5, 25, 99, and 90.9%, respectively. Similar values were observed using the neck CECT scan in detecting residual disease at the primary site (75, 90.6, 23.1, 99, and 90%, respectively) (Table 2) ( Fig. 1 and Fig 2) .
Ipsilateral neck
At the ipsilateral neck, TN, FN, TP, and FP were 102, 2, 3, and 3, respectively, for PET/CT and 70, 1, 4, and 35, respectively, for neck CECT. The sensitivity, specificity, PPV, NPV, and accuracy of PET/CT for detecting residual nodal disease at the ipsilateral neck were 60, 97.1, 50, 98.1, and 95.5%, respectively, whereas the neck CECT scan showed higher sensitivity for detecting residual disease at the ipsilateral neck, but lower specificity, PPV, NPV, and accuracy than that of PET/CT (80, 66.7, 10.3, 98.6, and 67.3%, respectively) ( Table 2) . Statistical analysis showed significantly higher PPV (P = 0.05) and higher specificity (P < 0.001) for the PET/ CT scan ( Fig. 3 and Fig. 4 ).
Contralateral neck
At the contralateral neck, TN, FN, TP, and FP were 106, 0, 2, and 2, respectively, for PET/CT and 102, 0, 2, and 6, respectively, for neck CECT. The sensitivity, specificity, PPV, NPV, and accuracy of PET/CT for detecting residual disease at the contralateral neck side were 100, 98.1, 50, 100, and 98.2%, respectively. There was a significant difference in the sensitivity of PET for contralateral nodal disease compared with ipsilateral nodal disease, likely related to the fewer number of nodes identified in the contralateral neck. PET/CT and neck CECT were quite similar (except for PPV, which was higher in PET/ CT). The sensitivity, specificity, PPV, NPV, and accuracy of the neck CECT scan for detecting residual disease at the contralateral neck were 100, 94.4, 25, 100, and 94.5%, respectively (Table 2) (Fig. 5) .
Overall accuracy
Besides the primary site and regional lymph node involvement, the PET/CT scan was also useful in evaluating any distant site of metastasis as it is a wholebody scan from the skull base to the mid-thigh. The sensitivity, specificity, PPV, NPV, and accuracy of PET/ CT for detecting residual disease at all sites were 77.8, 88.1, 36.8, 97.8, and 87.3%, respectively, for 18 F-FDG-PET/CT and 87.5, 59.8, 14.6, 98.4, and 61.8%, respectively, for neck CECT. Although neck CECT was more sensitive, using the method of interpretation used in this study, the PET/CT scan was more specific and more accurate in detecting residual disease in patients with OPSCC using the Hopkins Criteria for therapy assessment. Statistical analysis showed significantly higher overall specificity and accuracy for the PET/CT scan (P < 0.001 and 0.001).
Discussion
After the treatment of OPSCC with surgical resection, chemotherapy, or radiation therapy, changes in the normal tissue and anatomy (edema, hyperemia, and fibrosis) may affect the accuracy of imaging modalities in detecting residual disease [1] . Therapy assessment is an important step in the management of patients with OPSCC, as accurate confirmation of complete response can lead to discontinuation of treatment. However, early detection of residual disease leads to initiation of new treatment [17] . The results of this study showed that post-treatment PET/CT and neck CECT have similar accuracy in detecting residual disease at the primary tumor sites. Neck CECT was more sensitive for the neck A 73-year-old man with a history of T2 N2b squamous cell carcinoma of the left tonsil who underwent definitive chemoradiation (weekly carboplatin).
The treating physician requested a PET/CT (a, b) and CECT (c) for the evaluation of treatment response. The PET/CT scan was negative, whereas the CECT scan was suggestive of residual tumor in the neck (white arrow). Clinical follow-up of the patients confirmed that the suspicious lesion in the CECT was false positive. CECT, contrast-enhanced computed tomography; CT, computed tomography. A 40-year-old man with a history of T4 N3 squamous cell carcinoma of the right tonsil who underwent definitive chemoradiation. The treating physician requested a PET/CT (a, b) and CECT (c) for the evaluation of treatment response. The PET/CT scan was negative, whereas the CECT scan was suggestive of residual tumor in the neck (white arrow). Biopsy of the suspicious lymph node confirmed positivity (PET/CT false negative, CECT true positive). CECT, contrast-enhanced computed tomography; CT, computed tomography. A 54-year-old man with T4 N2c left tonsil squamous cell carcinoma, status post curative intent chemoradiotherapy (three cycles of cisplatin, cetuximab, and paclitaxel, followed by concurrent chemoradiation with carboplatin and 72 Gy of external-beam radiation therapy). The treating physician requested a PET/CT (a, b) and CECT (c) for the evaluation of treatment response. Both PET (arrows in a and b) and CECT (arrow in c) scans were positive for residual tumor in the neck, which was confirmed to be true positive by biopsy. CECT, contrast-enhanced computed tomography; CT, computed tomography.
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node residual disease detection whereas PET/CT has higher specificity and accuracy for detecting residual diseases in neck nodes using the interpretation methods in this study. The size, contrast enhancement, change in morphology, and necrosis were considered in reading the post-treatment CECT scans, whereas 18 F-FDG avidity in comparison with blood pool and liver was considered for reading the post-treatment PET/CT scans following the Hopkins Criteria.
In our study, the sensitivity, specificity, PPV, NPV, and accuracy in detecting residual disease were 77.8, 88.1, 36.8, 97.8, and 87.3%, respectively, for PET/CT imaging and 87.5, 59.8, 14.6, 98.4, and 61.8%, respectively, for neck CECT. Chen et al. [18] , in a small study, compared post-treatment PET/CT and CECT in patients with OPSCC and unknown primary head and neck SCC (total 30 patients). They reported a higher accuracy of CECT for the evaluation of the primary site (85.7 vs. 82.1%) and higher accuracy of PET/CT in the evaluation of the neck (59.3 vs. 74.1%) [18] . In another study, Suenaga et al. [19] included all the patients with head and neck cancers who had a PET/CT, CECT, or PET/CECT after the completion of treatment (2-78 months) for evaluation of suspected recurrence or active tumor. They reported that both PET/CT and PET/CECT had higher accuracy for detecting recurrence than CECT; moreover, PET/ CECT was reported to be the best modality in their study [19] . In a meta-analysis, Isles et al. [20] evaluated post-treatment and follow-up PET/CT scans in patients with head and neck cancers, reporting pooled sensitivity, specificity, PPV, and NPV of 94, 82, 75, and 95%, respectively. The results of PET/CT were not compared with that of CT; however, the results of CT, mostly without contrast, and MRI were provided and the values were significantly lower. The authors also claimed that the time between treatment and performing PET/CT scan was an important factor and the sensitivity of PET/ CT was higher for those scans performed later from the treatment completion [20] . Our results were very similar to those studies that only included the post-treatment scan within 6 months of completion of therapy [21, 22] .
Our results showed that although neck CECT was more sensitive, PET/CT was more specific and more accurate, with higher NPV for therapy assessment in patients with OPSCC. Multiple previous studies evaluated the value of PET/CT or CECT in the therapy assessment setting and reported acceptable accuracies [11, 23] . For instance, Rangaswamy et al. [14] evaluated 103 patients with different types of head and neck cancers including salivary gland cancers and skin cancers, and about 50% of their patients were diagnosed with OPSCC. They compared the recurrence detection rate of post-treatment diagnostic high-resolution computed tomography (HRCT), PET/ CT (low-dose CT), and PET/CT performed 18 months after treatment. Their results showed higher sensitivity, respectively, for PET/HRCT, PET/CT, and HRCT in recurrence detection of their heterogenous patient population [14] . In addition, a few studies comparing the accuracy of these two modalities without accounting for the same day PET/CT and CECT scans have been reported [24] [25] [26] [27] . In a prospective trial, Moeller et al. [28] claimed that PET/CT was not superior to the CECT scan in therapy assessment of patients with OPSCC. However, investigators enrolled OPSCC patients who were treated with radiation therapy, including PET/CT and CECT scans after 8 weeks of therapy completion [28] . This inclusion criterion (8 weeks) increases the number of FP results because of post radiation inflammation and inflammatory 18 F-FDG uptake. The timing of performing post-therapy imaging modalities is an important factor for therapy assessment. Inflammatory 18 F-FDG uptake could be decreased with time as the inflammation decreases progressively with time; therefore, performing PET/CT at a reasonable time-point after radiation treatment (>12 weeks) will decrease the likelihood of FP PET/CT results [29] [30] [31] . Enomoto et al. [13] evaluated 18 patients with OPSCC in another small prospective study and reported that PET/CT had higher accuracy than CECT in regional recurrence detection (94 vs. 78%), whereas the accuracies of both modalities were the same in local recurrence detection (83%).
The involvement of neck lymph nodes is common in HPV-related OPSCC patients, and these lymph nodes usually present with diverse morphologies such as solid, cystic, and necrotic features. Multiple characteristics of the CT scans are used to follow the neck lymph nodes after radiation therapy in patients with OPSCC, such as changes in volume, size, density (Hounsfield unit), heterogeneity, and other anatomical and morphological features. Although some of these features were useful in differentiating between the responders versus nonresponders, none of these features were shown to be promising in therapy response assessment [32] [33] [34] . The value of MRI was also evaluated in response evaluation of the neck in oropharyngeal cancer. In a retrospective cohort study, Lilja-Fischer et al. [35] , assessed the value of MRI in neck response assessment of 100 patients with advanced OPSCC. They reported a very low sensitivity and specificity for MRI in this setting (69 and 41%, respectively). They concluded that early anatomical imaging may be inappropriate for evaluating neck response in patients with HPV-related OPSCC [35] . In another study, ultrasound MRI and PET/CT were evaluated in the detection of neck residual disease in patients with OPSCC and concluded that PET/CT combined with neck ultrasound could be a reliable and costeffective strategy in this setting [36] . In terms of the CT scan, neck CECT scans could not differentiate between the residual disease-related and therapy-related changes such as necrotic and scar tissue [1, 37] . Finally, dental repair materials, that is, metal artifacts, may obscure the oropharyngeal area and decrease the value of a CECT scan in the therapy assessment setting [14, 15] . Considering all of these limitations, CECT is still useful in the management of patients with OPSCC.
However, PET/CT can differentiate the viable tumor from the necrotic and scar tissue as the latter does not uptake 18 F-FDG. The FP results of PET/CT because of inflammatory 18 F-FDG uptake can be decreased by performing the scan at a reasonable time-point after radiation therapy (>12 weeks) [31] . A common cause of treatment failure in OPSCC is undiagnosed distant metastasis and distant metastasis occurs in about 15-20% of the patients. PET/CT imaging is a whole-body imaging study and adds value for the evaluation of any distant metastasis (lung, liver, bone, etc.) at the same time [1] . However, all pitfalls of CECT will not be resolved by PET/CT because of some limitations as well. PET/CT may not detect small residual disease (< 10 mm) because of the low spatial resolution [31, 37, 38] . Therefore, a contrast-enhanced PET/CT scan may be the best option in some patients. It was shown that contrast-enhanced PET/CT decreases the need for a separate neck CECT scan and the scans can be performed in a single study session [1] . Overall individualizing a patient's risks and tumor characteristics would be crucial to decide on whether to perform PET/CT or CECT, or both in the therapy assessment of patients with OPSCC.
There are limitations to our study. We retrospectively included patients who underwent same-day posttreatment PET/CT and CECT scans. There is a possibility of selection bias. The clinician ordered both PET/ CT and CECT imaging likely because there was a higher concern for residual malignancy. Furthermore, we used the 6-month clinical follow-up as a reference standard when there was no histopathological confirmation. Moreover, biopsy sampling error in the suspicious lesions is a possibility, resulting in FN results. Our readers were blinded to the staging scans; some of the imaging therapy response criteria depend on the comparison of posttreatment scans with the pretreatment ones. This may decrease the reported accuracy of the readings.
Conclusion
Same-day PET/CT and neck CECT scans had comparable accuracy in the evaluation of primary tumor sites as part of the therapy assessment of patients with OPSCC, whereas PET/CT showed higher accuracy in the evaluation of neck lymph node involvement (Figs 1-5 ).
